XML 51 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Segment
Mar. 30, 2019
USD ($)
Dec. 28, 2019
USD ($)
Number of operating segments | Segment 1    
Clinical Trial Cost $ 713 $ 614  
Performance obligations totaled 700   $ 700
Research development and clinical trials expenses $ 400 $ 200  
Revenue, Performance Obligation, Description of Payment Terms Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 days for customers in the United States and 30 to 90 days for customers in non-U.S. markets, and such payments do not include payments that are variable, dependent on specified factors or events.    
Contract assets $ 0   $ 0
Revenue, Performance Obligation, Description of Timing The Company generally satisfies performance obligations within one year of the contract inception date.    
Accounts Receivable [Member] | Minimum [Member]      
Concentration Risk, Percentage 10.00%    
Revenue [Member] | Minimum [Member]      
Concentration Risk, Percentage 10.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]      
Concentration Risk, Percentage 17.00%    
Customer Concentration Risk [Member] | Revenue [Member] | Customer One [Member]      
Concentration Risk, Percentage 17.00% 13.00%  
Customer Concentration Risk [Member] | Revenue [Member] | Customer Two [Member]      
Concentration Risk, Percentage   11.00%